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Grafting Segments from the Extracellular Surface
of CCR5 onto a Bacteriorhodopsin Transmembrane
Scaffold Confers HIV-1 Coreceptor Activity
posed of a single polypeptide chain that is folded into
seven transmembrane (TM) segments connected by rel-
atively hydrophilic loops on the extracellular and cyto-
plasmic surfaces. At present, high-resolution structural
information is only available for the naturally abundant
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Brandeis University for structural studies have met with limited success.
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Irvine, California 92697 largely nonoverlapping functions of CCR5 [14–16]. Chi-
meras between CCR5 and divergent chemokine recep-
tors [14, 17–23] have revealed that the amino-terminal
region and one or more of the extracellular loops ofSummary
CCR5 are required for effective coreceptor function.
Similar findings have been obtained through anti-CCR5Components from the extracellular surface of CCR5
antibody mapping studies [19, 24, 25]. Amino acid sub-interact with certain macrophage-tropic strains of hu-
stitutions within the amino-terminal segment of CCR5man immunodeficiency virus type 1 (HIV-1) to mediate
disrupt CCR5-mediated fusion and entry of both R5 andviral fusion and entry. To mimic these viral interacting
R5X4 isolates [26–30]. Farzan et al. [31] have shown thatsite(s), the amino-terminal and extracellular loop seg-
tyrosine residues in this region of CCR5 are sulfatedments of CCR5 were linked in tandem to form concate-
and are required for optimal coreceptor function. Manynated polypeptides, or grafted onto a seven-trans-
mutations in this same region and in the extracellularmembrane bacteriorhodopsin scaffold to generate
loops that affect CC chemokine binding have also beenseveral chimeras. The chimera studies identified spe-
identified [32, 33].cific regions in CCR5 that confer HIV-1 coreceptor
While dissecting structural features of CCR5 that arefunction, structural rearrangements in the transmem-
required for coreceptor activity has received consider-brane region that may modulate this activity, and a role
able attention, studies focused on the folding and as-for the extracellular surface in folding and assembly.
sembly of CCR5 as well as the nature of the interactionsMethods developed here may be applicable to the dis-
between various extracellular segments of the receptorsection of functional domains from other seven-trans-
have been lacking. In this study, we utilized the domainmembrane receptors and form a basis for future struc-
approach developed for studying rhodopsin [34] in antural studies.
attempt to mimic the structure of the extracellular sur-
face of CCR5 that contributes toward HIV-1 coreceptor
Introduction function. For this purpose, the amino-terminal and extra-
cellular loop segments of CCR5 (Figure 1A) were linked
The CC chemokine receptor CCR5 confers susceptibility in tandem to form contiguous polypeptides, or grafted
to infection by certain macrophage-tropic strains of hu- singly, and in combination, onto a seven-TM bacterio-
man immunodeficiency virus type 1 (HIV-1) in the pres- rhodopsin (bR) scaffold (Figure 1B). The CCR5 extracel-
ence of CD4 [1–5]. HIV-1 entry into target cells is thought lular surface polypeptides (Table 1) and CCR5/bR chi-
to occur by the successive interaction of the envelope meras (Table 2) were expressed in E. coli or mammalian
glycoprotein (env) gp160/120 with CD4 and CCR5. Bind- cells and examined for stable expression, cellular local-
ing of env to CD4 presumably exposes a CCR5 binding ization, and/or retinal binding and coreceptor activities.
site on gp160/120 [6–8]. CCR5 and CXCR4, a related The results show that grafting the amino-terminal seg-
chemokine receptor, are the most widely used HIV-1 ment of CCR5, as well as the entire CCR5 extracellular
coreceptors [9, 10]. surface, onto a bR TM scaffold renders chimeras that
CCR5 is typical of the large family of G protein-cou- are capable of modulating CD4-dependent, gp160-
pled receptors (GPCRs). Over 700 distinct sequences mediated cell fusion. The enhanced coreceptor function
within the superfamily have been identified and many of of a chimera comprised of all four CCR5 extracellular
these receptors play key roles in cardiovascular disease, segments in the presence of retinal suggests that occu-
diabetes, hypertension, AIDS, and a variety of sensory pancy of the bR chromophore binding pocket induces
and mental disorders [11]. Like all GPCRs, CCR5 is com-
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Table 2. CCR5/bR Chimeras
Chimera or mutant CCR5 sequence
NTCCR5/bR 1–26
1stCCR5/bR 92–102
2ndCCR5/bR 166–191
3rdCCR5/bR 260–279
CCR5Ex/bR 1–26, 92–102, 166–191, 260–279
NTCCR5/bR (Y10, 14F) 1–26 (Y10, 14F)
NT1stCCR5/bR 1–26, 92–102
NT2ndCCR5/bR 1–26, 166–191
NT3rdCCR5/bR 1–26, 260–279
NT1st2ndCCR5/bR 1–26, 92–102, 166–191
NT1st3rdCCR5/bR 1–26, 92–102, 260–279
NT2nd3rdCCR5/bR 1–26, 166–191, 260–279
1st2nd3rdCCR5/bR 92–102, 166–191, 260–279
CCR5Ex/bR (Y10, 14F) 1–26, 92–102, 166–191, 260–279
(Y10, 14F)
CCR5 (Y10, 14F) 1–352 (Y10, 14F)
between the appended segments and assembly of the
seven-TM scaffold is a cooperative process.
Results
Design of CCR5 Extracellular Surface Minigenes
The main focus of this work was to mimic the structure
of the extracellular surface of CCR5 that contributes
toward HIV-1 coreceptor activity. Initially, a series of
minigenes encoding various extracellular surface poly-
peptides (Table 1) were constructed by linking frag-
ments corresponding to the amino terminus and extra-
cellular loops of CCR5 in tandem. The length and/or
composition of the segments included in these mini-
genes was partly based on the combined results of nu-
merous chimeric and mutagenesis studies [13–30].Figure 1. Extracellular Surface of CCR5 and the Ground State Struc-
ture of bR However, since the approximate membrane/solvent
(A) Segments from the amino terminus and extracellular loops of boundaries for the amino terminus and the extracellular
CCR5. The letters A–G denote the positions of seven TM helices and loops of CCR5 are not known with certainty, their design
the numbers indicate the amino acid position in full-length CCR5. was largely empirical. Since many of the extracellular
(B) Model for the three-dimensional structure of bR (Protein Data surface polypeptides encoded by these minigenes failed
Bank code 1C3W). Segments shown in red were replaced with the
to be expressed and/or maintain a stable conformationcorresponding regions from CCR5. The all-trans retinal chromo-
in solution, an alternative strategy that involved graftingphore is shown in magenta. EC, extracellular surface; CP, cyto-
plasmic surface. the amino-terminal segment and extracellular loops of
CCR5 onto a “generic” seven-TM scaffold was also in-
vestigated.
structural rearrangements in the TM helices that are
transmitted to the surface. Comparisons between chi- Purpose and Choice of bR as a Seven-TM Scaffold
meras with various combinations of CCR5 sequences for the Extracellular Surface of CCR5
revealed that the establishment of specific interactions Numerous studies on bR have provided mechanistic
insights into the function of this seven-TM light-driven
proton pump from Halobacterium salinarium (H. sali-
Table 1. CCR5 Extracellular Surface Polypeptides
narium) [35]. The availability of high-resolution struc-
Polypeptidea CCR5 sequence tures for bR [36–39], the relative ease of bacterioopsin
(bo) mutant overexpression in H. salinarium [40, 41], andCCR5Ex1 1–34, 84–106, 162–202, 256–283
the recent success in grafting the third cytoplasmic loopCCR5Ex2 1–31, 88–102, 166–197, 256–283
CCR5Ex3 1–31, 90–102, 168–197, 258–279 of rhodopsin onto bR [42] make it an appealing scaffold
CCR5Ex4 1–26, 92–102, 166–193, 260–279 for appending a functional domain(s) that mimics the
CCR5Ex5 1–26, 92–102, 166–191, 256–277 viral binding activities of CCR5. Since bR lacks amino
a A Gly/Pro or Gly/Ser linker(s) is inserted between the amino-termi- acid sequence homology with the GPCRs, the contribu-
nal segment and the three extracellular loops. A thrombin cleavage tions of endogenous amino acids to a particular ap-
site followed by a His6 tag is present at the carboxyl terminus of pended function can be largely excluded. Importantly,
the polypeptides.
bR contains an all-trans retinal (atr) chromophore that
CCR5/Bacteriorhodopsin Chimeras
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cells. Like E. coli-expressed CCR5Ex4, COS-1 cell-
expressed CCR5Ex4 was also insoluble and required the
presence of detergent for isolation from the membrane
fraction.
Since these polypeptide models failed to be stably
expressed or adopt an ordered conformation(s) in solu-
tion, it is likely that additional constraints (e.g., TM heli-
ces) are necessary for proper folding and assembly of
the extracellular surface. Therefore, the design and con-
struction of additional minigenes was not pursued. In-
stead, the information derived from these studies, and
from CCR5Ex4 and CCR5Ex5 in particular, was used
to devise a minimal set of CCR5 extracellular surface
segments that could be grafted onto the seven-TM bR
scaffold.
Expression and Cellular Localization
of the CCR5/bR ChimerasFigure 2. Expression of CCR5 Extracellular Surface Polypeptides
Heymann et al. [44] have shown that bo can be ex-(A) Expression of CCR5Ex4 and CCR5Ex5 in E. coli. Proteins from
pressed in COS-1 cells and reconstituted with atr touninduced (u) or induced (i) cells were visualized with Coomassie
blue. form a bR-like pigment (560 nm). Therefore, the genes
(B) Expression of CCR5Ex4 in COS-1 cells. Proteins from CCR5Ex4 for both bo and the CCR5/bR chimeras (Table 2) were
transfected cells or cells transfected with the pMT3 vector (mock) expressed in COS-1 cells and the resulting proteins were
were detected with an anti-His6 antibody and visualized by chemilu- compared with CCR5. COS-1 cell expression of CCR5minescence.
yields two proteins of 43 kDa and 40 kDa (Figure
3A). These same two bands have been observed by
Sodroski and coworkers [45] and represent the matureabsorbs maximally at 560–570 upon correct folding
and assembly of the bo apoprotein. If the inserted CCR5 (43 kDa) and precursor (40 kDa) forms of CCR5. As
shown in Figure 3C, bo produced in COS-1 cells mi-segment(s) perturbs the folding and/or assembly of bR,
the chimera will not form a bR-like chromophore. In- grated at a molecular mass of26 kDa, virtually identical
to that of native bR from H. salinarium. In contrast tospection of the 1.55 A˚ structure of bR [43] revealed that
amino acids 1–8 in the amino-terminal segment, 64–79 the CCR5Ex polypeptides, all of the CCR5/bR chimeras
(Table 2) were stably expressed in COS-1 cells and couldin the first extracellular loop, 128–130 in the second
extracellular loop, and 196–200 in the third extracellular be detected with an anti-bR antibody (Figures 3B and
3C). For NTCCR5/bR, minor amounts of some fasterloop could potentially be replaced with minimal struc-
tural perturbations (see highlighted sequences in Figure and slower migrating polypeptides were also apparent
(Figure 3B). These same bands could be detected with1B). Thus, the amino-terminal and extracellular loop seg-
ments from bR were replaced with corresponding seg- an anti-CCR5 antibody that recognizes the amino termi-
nus. CCR5Ex/bR, which contains the amino-terminal re-ments from CCR5 either singly, or in combination, to
form a series of CCR5/bR chimeras. gion and all three extracellular loops from CCR5,
showed a single polypeptide with both antibodies (Fig-
ures 3C and 3D).Expression of the CCR5 Extracellular
Surface Polypeptides Expression levels for the CCR5/bR chimeras were
compared with both CCR5 and bo. COS-1 cells typicallyCellular expression of the minigenes showed that only
CCR5Ex4 and CCR5Ex5 were stably produced in E. coli expressed 2  1011 mol of CCR5/mg of membrane
protein, while bo was expressed at a level of about two(Figure 2A). Presumably, the larger CCR5Ex1, CCR5Ex2,
and CCR5Ex3 polypeptides are unable to fold to a con- to four times higher. For the CCR5/bR chimeras, the
levels of expressed protein were between CCR5 and boformation that resists degradation by cellular proteases.
Although the CCR5Ex4 and CCR5Ex5 polypeptides and ranged from 4  1011 to 8  1011 mol/mg of
membrane protein. Thus, single or multiple replace-were expressed at greater than 1 mg per 100 ml shake-
flask culture, both polypeptides were found in inclusion ments of components from the extracellular surface of
bR with corresponding segments from CCR5 appearedbodies. Upon solubilization, both CCR5Ex4 and CCR5Ex5
could be partially “refolded” into a form that was amena- to have no adverse effects on protein expression or
stability.ble to purification in the presence of detergent. However,
maintaining the solubility of the purified polypeptides For coreceptor assays (see below), it was important
to establish whether the CCR5/bR chimeras were pres-was technically challenging, as they formed higher mo-
lecular weight aggregates that eventually precipitated ent on the cell surface. For this purpose, CCR5, bo, and
selected CCR5/bR chimeras were tagged with GFP andupon storage. CCR5Ex4 was the only extracellular sur-
face polypeptide stably produced in COS-1 cells (Figure examined for cellular localization. While GFP showed
a diffuse pattern of fluorescence throughout the cells,2B). As noted above, it is likely that CCR5Ex1, CCR5Ex2,
CCR5Ex3, as well as CCR5Ex5 do not fold to a confor- CCR5, bo, and NTCCR5/bR (Figure 4) all showed consid-
erable fluorescence at the cell surface. Similar cell sur-mation that resists proteolytic degradation in COS-1
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Figure 3. Expression of CCR5/bR Chimeras
in COS-1 Cells
CCR5 and the CCR5/bR chimeras were de-
tected with the rho 1D4 (A), BR114 (B, C, and
E), or H1001 (D) antibodies and visualized by
chemiluminescence. Extracts from cells trans-
fected with the pMT3 vector (mock) served
as control. HsbR, H. salinarium bR.
face expression patterns were obtained with many of For NTCCR5/bR and NT3rdCCR5, the level of chromo-
phore formation was in the range of 70%–80%, assum-the other CCR5/bR chimeras, including CCR5Ex/bR,
suggesting that replacement of the bo amino terminus ing an extinction coefficient similar to monomeric bR.
For 3rdCCR5/bR, the level of regeneration was moreand/or the extracellular loops did not interfere with cellu-
lar trafficking. difficult to estimate because of multiple chromophores.
However, based on the absorbance at550 nm, greater
than 45% of the protein appeared to form a bR-likeCCR5/bR Chimera Chromophore Formation
with All-trans Retinal chromophore.
Both 1stCCR5/bR (Figure 5) and 2ndCCR5/bR pro-Addition of atr to membranes prepared from COS-1 cells
expressing bo resulted in the formation of a bR-like duced pigments with atr which showed a maximal ab-
sorption of 450–460 nm. Similar results were obtainedpigment (max560 nm), while similar treatment of mem-
branes from mock-transfected COS-1 cells showed no with the NT1stCCR5/bR, NT2ndCCR5/bR, NT1st2ndCCR5/
bR, NT1st3rdCCR5/bR, NT2nd3rdCCR5/bR, andbR-like chromophore (Figure 5). Based on the ab-
sorbance at 560 nm and comparative immunoblotting, 1st2nd3rdCCR5/bR chimeras. Surprisingly, however,
CCR5Ex/bR formed an 550 nm chromophore, albeit ataround 80%–85% of the bo formed a chromophore. For
NTCCR5/bR, 3rdCCR5/bR, and NT3rdCCR5/bR (Figure a low level when compared with bR formed by addition
of atr to the isolated membranes (Figure 5). However,5), an 540–550 nm chromophore was formed upon
addition of atr. A second absorbing species (max 480 when CCR5Ex/bR was reconstituted “in vivo” by addi-
tion of atr to the media, the level of chromophore forma-nm) was also apparent in the 3rdCCR5/bR pigment. The
ratio between the 480 nm and 550 nm chromophores tion improved by more than an order of magnitude such
that greater than 90% of the apoprotein produced bounddid not change with time or exposure to additional atr.
Figure 4. Cellular Localization of GFP-Tagged
CCR5/bR Chimeras
Cells cotransfected with GFP (A), GFP-
tagged CCR5 (B), bo (C), or NTCCR5/bR (D),
and CD4 and luciferase plasmids, were exam-
ined under an Olympus IX-70 fluorescence
microscope with a 40 objective approxi-
mately 45 hr posttransfection. Representative
photographs are shown.
CCR5/Bacteriorhodopsin Chimeras
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Figure 5. UV/Visible Spectroscopy of COS-1 Cell-Expressed Bo and CCR5/bR Chimeras
Membranes from cells transfected with the indicated genes were regenerated with atr. For CCR5Ex/bR, atr was also added directly to the
media prior to harvesting and membrane preparation. Representative spectra are shown.
retinal (Figure 5). Similar treatment of COS-1 cells ex- ond, or third extracellular loops with those from CCR5, or
a combination of these replacements (1st2nd3rdCCR5/pressing bo, NTCCR5/bR, 3rdCCR5/bR, or NT3rdCCR5/
bR showed no significant differences in the extent of bR), showed no significant coreceptor activity above
basal levels. Thus, while swapping the amino terminus ofregeneration from the pigments formed by addition of
retinal to the membranes. Thus, formation of a bR-like bR with that from CCR5 is sufficient to confer coreceptor
function, in the context of the other loops that comprisechromophore in CCR5Ex/bR occurs much more readily
during folding and assembly of the chimeric apoprotein the remainder of the CCR5 extracellular surface, the
amino-terminal gp120 binding site appears less acces-than in the folded structure. Taken together, these find-
ings indicate that while individual replacement of the first sible.
The effect of atr on CCR5/bR coreceptor activityand second extracellular loops with the corresponding
segments of CCR5 perturbs the overall seven-TM struc- showed that only cells expressing the CCR5Ex/bR chi-
mera exhibited a significant increase in coreceptor activ-ture of bR, introduction of these same two segments
into NT3rdCCR5/bR (to yield CCR5Ex/bR) results in the ity after addition of atr (Figure 7). Although such retinal-
dependent changes in coreceptor activity could be acooperative formation of a CCR5 extracellular surface
that allows correct alignment of the bR TM helices and consequence of enhanced cell surface expression, it
is more likely that they reflect structural changes thatconsequently, formation of the retinal binding pocket.
influence the conformation of the amino-terminal gp120
recognition site.CCR5/bR Chimera Coreceptor Activity
The effects of individual CCR5 extracellular loops onCCR5 exhibited CD4-dependent, JRFL-gp160-mediated
the coreceptor activity of NTCCR5/bR as well as muta-coreceptor function, while mock-transfected cells showed
tions at Tyr-10 and Tyr-14 on the activity of CCR5,no appreciable level of activity (Figure 6). For bo trans-
NTCCR5/bR, and CCR5Ex/bR were also examined (Figurefected cells, a small, variable amount of coreceptor ac-
8). Individual replacement of each of the three bR extracel-tivity was apparent and ranged from essentially no activ-
lular loops in NTCCR5/bR with the corresponding loopity above that observed for mock transfected cells to
from CCR5 led to a marked decrease in coreceptor func-around 20% the level obtained with CCR5. In contrast,
tion. This result was not unexpected for NT1stCCR5/bRsignificant coreceptor function was apparent for cells
and NT2ndCCR5/bR, since these loop replacements ap-expressing NTCCR5/bR, often at levels exceeding the
pear to perturb the folding of the protein as judgedactivity of native CCR5. For cells expressing CCR5Ex/
by the lack of bR-like chromophore formation with atr.bR, CD4-dependent coreceptor activity above basal and
However, for NT3rdCCR5/bR, this marked decrease inbo levels was also apparent, but to a lesser degree than
coreceptor activity was rather surprising since this chi-observed for CCR5 and NTCCR5/bR. Interestingly, the
mera is able to form an 550 nm chromophore withGFP-tagged versions of these chimeras (as well as CCR5)
atr. This was evident regardless of whether the cellsshowed moderately higher levels of coreceptor function.
expressing this chimera were exposed to retinal. Phenyl-Although the reason for this is not clear, it may be due
alanine substitutions at Tyr-10 and Tyr-14 in the aminoto increased cell surface expression. CCR5/bR chimeras
containing individual replacements of the bR first, sec- terminus markedly reduced, but did not abolish, CCR5
Structure
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Figure 6. CD4 Dependence of CCR5 and
CCR5/bR Chimera Coreceptor Activities
coreceptor activity. These 2 residues are the primary the amino terminus is an important determinant of CCR5
coreceptor function that is modulated by interactionssites of CCR5 tyrosyl sulfation, and the absence of this
with one or more of the extracellular loops. Here, wemodification has been shown to compromise corecep-
investigated whether specific segments from the extra-tor function [31, 46, 47]. These substitutions result in a
cellular surface of CCR5 could mimic the coreceptornoticeable increase in CCR5 migration upon SDS-PAGE
function of the intact receptor when linked as contiguousanalysis (Figure 3A), presumably due to the loss of the
polypeptides or grafted onto a bR seven-TM scaffold.negatively charged sulfate moieties. Similar functional
A major challenge in this study was to effectively de-and electrophoretic results were obtained for NTCCR5/
fine the amino acid sequence and/or length of the CCR5bR(Y10, 14F) and CCR5Ex/bR(Y10, 14F) (Figures 3E and
segments that could be grafted as well as the extracellu-8), as well as their GFP-tagged counterparts, suggesting
lar sequences on the bR TM scaffold that could be re-that interactions between these CCR5/bR chimeras and
placed. Although many of the regions and in some casesJRFL-gp160 are highly specific.
amino acid residues on CCR5 important for coreceptor
function have been identified, selection of those seg-Discussion
ments to include in the extracellular surface polypeptide
models or the CCR5/bR chimeras was largely empirical.Structure/function studies of CCR5 have relied mostly
A series of minigenes encoding varying segments fromon the characterization of receptor chimeras and point
the extracellular surface of CCR5 (Figure 1A) were ini-mutants. The emerging consensus so far has been that
tially constructed. Since the bulk of these polypeptides
failed to be stably expressed, it became clear that the
amino terminus and extracellular loop regions in these
polypeptides did not contain sufficient information to
fold to a stable and/or relatively ordered conformation.
However, the results of these studies provided some
clues into the minimum set of CCR5 extracellular se-
quences (i.e., a hybrid between CCR5Ex4 and CCR5Ex5)
that could potentially be grafted onto the seven-TM bR
scaffold. For bR, key insights into which segments could
be replaced with corresponding segments from CCR5
(Figure 1B) were afforded by examining the highest reso-
lution ground state three-dimensional structure cur-
rently available [43].
Selective replacement of the amino terminus of
bR with the amino terminus of CCR5 resulted in signifi-
cant coreceptor activity, often at levels exceeding that
of CCR5 (Figure 6). Optimal coreceptor activity was de-
pendent upon the presence of CD4 and tyrosine resi-
dues at positions 10 and 14, presumed tyrosyl sulfation
sites. Because NTCCR5/bR involved exchanges be-
tween unrelated receptors of very different sequence,
it is clear that grafting the amino terminus of CCR5 ontoFigure 7. Effect of Atr on CCR5Ex/bR Coreceptor Activity
CCR5/Bacteriorhodopsin Chimeras
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Figure 8. Effect of the Third Extracellular Loop
and Amino-Terminal Mutations on CCR5,
NTCCR5/bR, and CCR5Ex/bR Coreceptor
Activities
the first TM of bR is sufficient to mimic the coreceptor was not detrimental to folding, assembly, and cellular
trafficking of the protein. The lack of coreceptor activityfunction of native CCR5. These results are consistent
with the view that a single contact site on the amino- associated with this chimera suggests that the third
extracellular loop either does not participate in the inter-terminal segment of CCR5 rather than a complex extra-
cellular surface structure may be responsible for gp120 action with gp120 or presents a conformation that is
different from that found on CCR5. Combining all threebinding [25–29]. The slightly higher level of coreceptor
activity observed for NTCCR5/bR compared to CCR5 of the extracellular loops to form a 1st2nd3rdCCR5/bR
chimera also resulted in negligible coreceptor function.may reflect the absence of tertiary structure interactions
that render the gp120 interaction site more accessible. In the absence of atr, cells transfected with the
CCR5Ex/bR chimera exhibited a low level of CD4-Significant decreases in coreceptor activity were ap-
parent in chimeras containing both the amino terminus dependent coreceptor activity (Figure 6). However, re-
generation of cells expressing CCR5Ex/bR with atr con-and the first, second, or third extracellular loops of
CCR5. For NT3rdCCR5/bR, this finding was surprising ferred a significant increase in this activity (Figure 7).
This retinal dependence on coreceptor function was notgiven that this chimera forms a bR-like chromophore
with atr (Figure 5) and shows abundant cell surface ex- apparent with any other chimera, including NTCCR5/
bR. Here, it is possible that the retinal chromophorepression. Although it is not clear as to why NT3rdCCR5/
bR shows reduced coreceptor activity (Figure 8), it is repositions the seven TM helices in CCR5Ex/bR to mod-
ulate interactions between the amino-terminal gp120possible that interactions between these two extracellu-
lar segments precludes a productive interaction with binding site and distal portions of the CCR5 extracellular
surface. Whether this is coupled to trimer formation, asgp160/120. It has been proposed that Cys-20 in the
amino terminus of CCR5 and Cys-269 in the third extra- is characteristic for bR, is not known at the present time.
Clearly, the level of CCR5Ex/bR coreceptor activity iscellular loop form a disulfide bond [33]. Although it is
not known whether these two Cys residues also form a not as robust as native CCR5. One plausible explanation
for this behavior is that although the bR seven-TM scaf-disulfide bond in NT3rdCCR5/bR, it is likely that any
conformational strain on the amino terminus would com- fold provides a degree of stability to the appended
loops, it may deprive them of the finely tuned structuralpromise the coreceptor function of this chimera. It is
also possible that addition of the third extracellular loop flexibility that the CCR5 TM segments have to offer. This
likelihood is further suggested by comparisons betweento NTCCR5/bR adversely affects tyrosyl sulfation.
Clearly, the chemical and/or structural basis for reduced the ground state three-dimensional structures of bR [43]
and bovine rhodopsin [12]. Although there is reasonableNT3rdCCR5/bR coreceptor activity deserves further
study. superposition among the first three TM helices, the re-
maining portions of the structures show considerableIndividual replacements of the first, second, or third
loops of bR with the corresponding CCR5 loops did not divergence. The crystal structure of rhodopsin also re-
veals that the amino terminus forms a  strand that isconfer any coreceptor function. In the case of 1stCCR5/
bR and 2ndCCR5/bR, this was not too surprising since in contact with all three extracellular loops. By analogy,
the extracellular surface of CCR5Ex/bR may share athese chimeras failed to form a bR-like chromophore with
atr, indicative of improper folding. However, 3rdCCR5/ similar structural motif.
Without exception, chimeras with replacement(s) of thebR formed a bR-like chromophore (Figure 5) and was
transported to the cell surface, suggesting that replace- amino terminus and/or the third extracellular loop showed
540–550 nm chromophores. In contrast, chimeras withment of the small bR loop with the larger CCR5 loop
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first and/or second bR loop replacements often yielded based on soluble domain models or chimeras with suit-
ably similar yet functionally distinct membrane proteins450–460 nm chromophores, the only exception being
CCR5Ex/bR (Figure 5). Recent studies by Booth, Khorana, that are more amenable to overexpression and crystalli-
zation may facilitate efforts at elucidating the structuraland colleagues [48, 49] have suggested that the first and
third extracellular loops of bR are the most critical for details of viral recognition. The CCR5/bacteriorhodop-
sin (bR) chimeras reported here show that replacementstability and proper chromophore formation. The present
findings clearly show that replacement of the first and of the amino terminus of bR with the corresponding
region from CCR5 is necessary and sufficient to confersecond extracellular bR loops with the corresponding seg-
ments from CCR5 have the greatest impact on chimera CD4-dependent, gp160/120-mediated coreceptor func-
tion. Furthermore, coreceptor activity appears to befolding and assembly. Perhaps the most striking result
from these studies is that simply adding the CCR5 amino modulated by structural rearrangements in the bR trans-
membrane scaffold in a chimera comprised of the entireterminus to the 1st2nd3rdCCR5/bR chimera (to form
CCR5Ex/bR) yields an550 nm bR-like pigment. These CCR5 extracellular surface. These clear demonstrations
of acquired coreceptor function suggest that there is afindings strongly suggest that formation of an extracellu-
lar surface structure comprised of the amino terminus reasonable degree of compatibility between appended
segments from the extracellular surface of CCR5 andand all three extracellular loops is important for correct
folding and assembly of the chimeric protein. This likeli- the transmembrane region of bR. The amino-terminal
region of CCR5 also appears critical for forming tertiaryhood is further supported by the observation that
“folded” CCR5Ex/bR shows considerably lower levels contacts with the other extracellular loops to influence
folding and assembly of the chimeric receptor. This ob-of chromophore formation with atr than the protein un-
dergoing folding and assembly (Figure 5). Previous stud- servation is consistent with biochemical and structural
data on homologous receptors from the same family.ies using bR fragments have suggested a two-stage
model for membrane protein folding in which the TM Collectively, these findings suggest that bR can be used
as an effective structural template for the extracellularhelices fold independently of each other and following
their membrane insertion, assemble without major re- surface of CCR5 and that such a strategy may prove
useful for addressing the importance of specific do-arrangements to form a functional protein [50]. Although
this mechanism appears applicable to native bR and mains in the folding, assembly, and function of a number
of pharmacologically tractable membrane receptors.other predominantly -helical polytopic membrane pro-
teins, folding and assembly in CCR5Ex/bR more closely
resembles that of the GPCR rhodopsin, where formation Experimental Procedures
of a specific extracellular surface structure and assem-
Construction of CCR5 Mutants, Minigenes, and Chimerasbly of the seven TM helices are coupled [51–53]. In fact,
A synthetic human CCR5 gene, modified to contain the carboxy-it could be argued that formation of such an extracellular
terminal 9 amino acid rho 1D4 epitope from bovine opsin, was ligated
tertiary structure in this chimera dominates over helix- into the pMT3 expression vector [54] and used to prepare CCR5
helix interactions in the folding pathway. mutants containing the Tyr-10 and Tyr-14 to Phe substitutions by
restriction fragment replacement. Oligonucleotides were synthe-The CCR5/bR chimeras described here show that
sized on an Applied Biosystems 394 DNA synthesizer and purifiedthere is sufficient flexibility in the bR seven-TM bundle to
by HPLC. The synthetic gene was also used to prepare fragmentsaccommodate substantial changes on the extracellular
of CCR5 that were either (1) joined to form minigenes or (2) intro-surface. Whether other seven-TM scaffolds can be simi-
duced by restriction fragment replacement into the synthetic bo
larly exploited to append segments from the extracellu- gene [55]. The minigenes also contained sequences encoding a
lar surface of CCR5 or other GPCRs is of considerable His6 carboxy-terminal fusion separated by a thrombin cleavage site
(LVPRGS). Wild-type and mutant CCR5 genes, as well as selectedinterest. Since it is difficult to envision how the extracel-
CCR5/bR chimeras, were also modified at the carboxyl terminus,lular surface on some of the CCR5/bR chimeras may be
with GFP obtained from the pBS-GFP5 vector [56]. DNA sequencesfunctionally organized, future studies directed toward
were confirmed using the PRISM dye terminator cycle sequencingtheir overexpression in H. salinarium, crystallization, and
method on an ABI model 373A automated DNA sequencer.
subsequent structure determination in the absence or
presence of interacting proteins may provide insightful
E. coli Expression and Purification of CCR5 Extracellular
answers to these concerns. Surface Polypeptides
The CCR5 minigenes were expressed in E. coli using the pHPTRX
expression vector [57] devoid of the thioredoxin gene. Competent
GI934 cells were transformed with the various minigenes and platedBiological Implications
on minimal media plates containing ampicillin. A single colony was
isolated and a 100 ml culture was grown and induced as describedCCR5 and CD4 are essential components of the HIV-1
[57]. Cell pellets were resuspended in 20 ml of 50 mM Tris-HCl (pHentry portal into human cells. This portal is recognized
7.5) containing 100 mM NaCl, a Complete protease inhibitor tablet
by the viral cell surface glycoprotein gp160/120, via a (Roche Applied Science), and 0.1 mM phenylmethylsulfonyl fluoride
CD4-assisted binding to the extracellular surface of (PMSF), and disrupted in a French pressure cell. For those cells
stably expressing the CCR5 extracellular surface polypeptides, theCCR5. Despite advances in the structural analysis of
supernatants were discarded and the pellets (inclusion bodies) wereCD4 and gp120 [65–67], such molecular level informa-
washed three times with 25 mM Tris-HCl (pH 7.5) containing 500tion is nonexistent for CCR5. This is partly due to the
mM NaCl, 2 mM dithiothreitol (DTT), and protease inhibitors followedlow natural abundance of CCR5 and is further com-
by an additional three washes with 100 mM Tris-HCl (pH 8.0) con-
pounded by difficulties associated with eukaryotic taining 2 mM DTT and 0.1 mM PMSF. Pellets were solubilized for
membrane protein overexpression and crystallization. 16 hr at 20C in 5 ml of 100 mM Tris-HCl (pH 8.0) containing 6 M
guanidinium hydrochloride, 300 mM DTT, and 0.1% (v/v)Functional mimics for the extracellular surface of CCR5
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N,N-dimethyldodecylamine-N-oxide (LDAO). The NaCl concentra- ity in this assay was judged by an increase in luciferase activity
when target cells were mixed with JRFL-gp160 effector cells. Basaltion of the sample was adjusted to 500 mM and the CCR5 extracellu-
lar surface polypeptides were purified on Ni2-nitriloacetic acid resin luciferase activity was measured when target cells were incubated
with effector cells cotransfected with pMT3 and T7 polymerase(Qiagen) essentially as described [34] except that 0.001% (v/v) LDAO
was present in the column running and elution buffers. The eluted plasmids or when target cells were incubated without effector cells.
For retinal dependence assays, 10 M atr was added to the mediaproteins were concentrated (Centriplus-10, Millipore) and purified
on PD-10 gel filtration columns (Bio-Rad) in 20 mM Tris-HCl (pH 7.5) 30–45 min after mixing target and effector cells. Results are pre-
sented as means	SEM of triplicate determinations from two to fourcontaining 100 mM NaCl, 2 mM DTT, 0.001% (v/v) LDAO, and 0.1
mM PMSF. independent experiments. Data were normalized to the coreceptor
activity of CCR5 in the absence of atr, which was assigned a value
of 1.0.COS-1 Cell Expression of CCR5, Minigenes, and Chimeras
CCR5, bo, CCR5 extracellular surface polypeptides, and CCR5/bR
chimeras were expressed in COS-1 cells as described [58]. Trans- Fluorescence Microscopy of GFP-Tagged CCR5, CCR5
Mutants, and Chimerasfected cells were harvested 55–72 hr after addition of DNA and
washed with phosphate-buffered saline. Cells that were mock trans- Target cells cotransfected with GFP-tagged CCR5, bo, or CCR5/
bR chimeras, CD4, and luciferase plasmids were examined underfected with the pMT3 vector served as controls.
an Olympus IX-70 fluorescence microscope with a 40 objective
approximately 45 hr posttransfection. Representative photographsQuantitation of CCR5, Extracellular Surface Polypeptides,
were taken with an Olympus SC35 camera.and Chimera Expression Levels
Cells were solubilized in 1% (w/v) SDS or dodecyl maltoside (DM)
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